Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, today announced the presentation...

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...

Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Research Triangle Park, NC, USA and Cambridge, UK, 11 January 2022 -- Inivata, a leader...